阿托伐他汀治疗急性缺血性脑梗死患者血浆溶血磷脂酸水平变化的研究

Changes of Plasma Lysophosphatidic Acid Levels in Patients with Acute Ischemic Cerebral Infarction Treated with Atorvastatin

目的研究阿托伐他汀对急性缺血性脑梗死的治疗效果及血浆溶血磷脂酸(LPA)水平的影响。方法随机数字法将64例急性缺血性脑梗死患者分为观察组与对照组,对照组给予常规治疗,观察组在对照组基础上加以阿托伐他汀治疗,比较两组临床疗效、治疗前后NIHSS评分、血脂指标、血浆LPA水平变化,并评价治疗安全性。结果观察组治疗总有效率93.75%比对照组的75.00%差异有统计学意义(P<0.05);观察组治疗后NIHSS评分、血浆LPA水平分别为(12.34±1.15)分、(2.16±0.78)μmol/L,与对照组的(15.59±1.20)分、(3.69±1.00)μmol/L比较差异有统计学意义(P<0.05);与治疗前比较,两组治疗后TC、LDL-C水平均显著下降(P<0.05),且观察组治疗后上述指标均显著低于对照组(P<0.05);两组均无肝肾功能异常、恶心呕吐等不良反应发生。结论阿托伐他汀治疗急性缺血性脑梗死效果较好,能明显改善患者神经功能缺损症状,这可能与阿托伐他汀调脂、降低血浆LPA水平有关。

Objective To study the effect of atorvastatin on the treatment of acute ischemic cerebral infarction and the effect on plasma lysophosphatidic acid LPA level. Methods 64 cases with acute ischemic cerebral infarction were randomly divided into the observation group and the control group with random number table method. The control group were given routine treatment, and the observation group were additionally treated with atorvastafin. The clinical efficacy, NIHSS scores before and after treatment, serum lipids, plasma LPA levels were compared between the two groups. The treatment safety was evaluated. Results The total effective rate of treatment in the observation group was 93.75%, while in the control group that was 75.00% P 0.05 . After treatment, the NIHSS score and plasma LPA level in the observation group were significantly lower than those in the control group [ 12.34 ± 1.15 , 2.16 ±0.78 μmol/L vs 15.59 ± 1.20 , 3.69 ± 1.00 μmol/L ] P 0.05 . After treatment, levels of TC, LDL- C in the two groups were significantly lower than those before treatment P 0.05 , and the above levels were significantly lower in the observation group than those in the control group P 0.05 . There was no adverse reaction, such as abnormal liver and kidney function, nausea and vomiting in the two groups. Conclusion Atorvastatin is effective in the treatment of acute ischemic cerebral infarction. It can significantly relieve symptoms of neurologic impairment, which may be related to atorvastatin regulating lipids, decreasing plasma LPA level.